Vector Science And Therapeutics Corp. · TSXV:PAIN
Vector Science And Therapeutics — Investor Presentation (July 2026)
42 slides from Vector Science And Therapeutics's investor presentation, July 2026
Slide 1: Bringing the Science of Precision to Therapeutics
INVESTOR PRESENTATION Bringing the Science of Precision to Therapeutics The Peptide Revolution, Engineered. TSXV: PAIN COMMERCIAL-STAGE MULTI-PRODUCT TSX Venture Exchange · Q2 2026 listing Lead product in market Pipeline in development Mequon, Wisconsin · vectorscience.co July 2026
Slide 2: Forward-Looking Information · Safe Harbour Statement
FORWARD-LOOKING INFORMATION · SAFE HARBOUR STATEMENT This presentation contains "forward-looking Forward-looking information is based on Although management believes the assumptions and information" within the meaning of applicable management's current estimates, assumptions, and expectations reflec
Slide 3: About Vector Science & Therapeutics Corp.
About Vector Science & Therapeutics Corp. Vector Science & Therapeutics Corp., headquartered in Mequon, Wisconsin, develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are una
Slide 4: Smart · Steered · Sustained
OUR APPROACH Smart · Steered · Sustained Three principles define how Vector delivers therapeutic advantage across every product in the portfolio. SMART STEERED SUSTAINED Adaptive. Data-driven. Patient- Continuous effect. No compliance Site-directed. On target. responsive. required. Vector portfolio
Slide 5: Mission: Bringing the Science of Precision to Therapeutics
MISSION Bringing the Science of Precision to Therapeutics Biomechanical devices + active transdermal therapeutic delivery → targeting the site, not the system. WHY WE DO IT HOW WE DO IT WHY WE'RE EQUIPPED We improve patient outcomes by Smart · Steered · Sustained. Platforms The Vector team brings de
Slide 6: A Staged Platform and Go-To-Market Strategy
PRODUCT PIPELINE A Staged Platform and Go-To-Market Strategy Five verticals spanning active peptide production through early discovery, each built on Vector's core delivery architecture. 01 02 03 04 05 ACTIVE · JULY/AUG 2026 COMMERCIAL Q4 2026 PIPELINE Q4 2027 PIPELINE DISCOVERY Peptide Production V
Slide 7: Four Markets. Non-Systemic Delivery.
MARKET OPPORTUNITY Four Markets. Non-Systemic Delivery. Vector platforms target ~12–21% of each TAM — the clinically addressable fraction reachable via site-directed, non-systemic delivery. Market / Status TAM Non-Systemic Component Vector Capture (5-Yr SOM) Perioperative Pain $420M $45B $7B · ~15%
Slide 8: Net Revenue by Product Line
Net Revenue by Product Line Three-year projection ($USD millions) · 186% two-year CAGR $2,000M ▲ +174% YoY $1,800M $222.2M $1,600M $1,400M Year 1 Net Revenue $1,200M $1,000M $800M $663.0M ▲ +198% YoY $600M Year 2 · ▲+198% YoY $400M $200M $0M $1.82B Year 1 Year 2 Year 3 Valor Peptide Convenience Pack
Slide 9: One Agreement. Vector's Entire Peptide Supply Chain.
STRATEGIC MILESTONE · BINDING SUPPLY & IP AGREEMENT One Agreement. Vector's Entire Peptide Supply Chain. Vector has entered into a binding agreement with LyoGenesis Plus, its cGMP lyophilization partner in Mequon, Wisconsin. VECTOR CONTRIBUTES LYOGENESIS COMMITS DEAL STRUCTURE 100% of Peptide Produc
Slide 10: Size of the Prize in Peptides
‘'7 v VECTOR SCIENCE & THERAPEUTICS Size of the Prize in Peptides
Slide 11: Peptide Market Growth Trajectory, 2020–2035
Peptide Market Growth Trajectory, 2020–2035 $250B 225 ~9% CAGR Consensus annual growth rate through 2033 (Grand View Research) $200B 165 280+ $150B Peptide candidates in preclinical & clinical 130 development globally 102 $100B 88 $1B+ 67 Genentech–peptide conjugate deal — signaling 56 46 capital co
Slide 12: Segment Breakdown & Vector's Strategic Position
Segment Breakdown & Vector's Strategic Position MARKET BY THERAPEUTIC AREA (2025) VECTOR'S POSITION Metabolic & Endocrine 35% cGMP Manufacturing Oncology 28% Mequon, WI production facility purpose-built for peptide synthesis — enabling scalable, compliant supply for the Valor commercial Cardiovascul
Slide 13: What the Industry Is Saying
What the Industry Is Saying “We are just now seeing peptides reach “The peptide manufacturing workforce needs “The next five years will bring significant commercial product stages and have these to triple by 2028 to keep pace with GLP-1 change for the peptide industry. Companies amazing effects… pep
Slide 14: Public Peptide Company Landscape
Public Peptide Company Landscape Company Ticker Mkt Cap Primary Focus Indication MEGA-CAP — GLP-1 / BROAD PEPTIDE Novo Nordisk NVO ~$200B+ Metabolic / Obesity — GLP-1 (semaglutide) Diabetes, Obesity Diabetes, Obesity, Eli Lilly LLY ~$700B+ Metabolic / Oncology — GLP-1/GIP (tirzepatide) Cancer Pfizer
Slide 15: Peptide Market Players & Vector's Position
TELEMEDICINE & DTC Peptide Market Players & Vector's Position Hims & Hers Health LifeMD Ro / Henry Meds / Noom HIGH REGULATORY EXPOSURE MEDIUM EXPOSURE HIGH REGULATORY EXPOSURE NYSE: HIMS · ~$7.8B NASDAQ: LFMD · ~$170M Private · Est. $5B+ combined Largest DTC telehealth platform, $2.35B Mid-tier tel
Slide 16: Public Peptide Company Landscape
Public Peptide Company Landscape Company Ticker Mkt Cap Primary Focus Peptide Platform Indication Crinetics Pharma CRNX ~$3.5B Rare endocrine disease Oral GPCR-targeting peptides Acromegaly, NET Rhythm Pharma RYTM ~$1.5B Rare genetic obesity MC4R peptide agonist Rare obesity (POMC, LEPR) Musculoskel
Slide 17: Supply, Scale & Economics
Supply, Scale & Economics Vector is building out commercial distribution of pharma-grade peptides. Supply and wholesale demand is expected to be robust. 800K ~$15 ~$80–$150 Vials / Month Capacity Cost Per Vial Avg. Wholesale Price cGMP pharma-grade peptide production Approximate production cost per
Slide 18: The Peptide Revolution
The Peptide Revolution $141B $295B 60% 2025 Global Market Projected by 2033 North America Share Peptide therapeutics now rival A ~9% CAGR over the next decade The U.S. leads global peptide traditional small-molecule drug classes reflects record M&A activity, commercialization, supported by in commer
Slide 19: Addressing the Factors of Competition in Peptides
Addressing the Factors of Competition in Peptides ✓ Factor of Competition Why It Matters Vector's Response cGMP certification is the price of admission, and capacity is Owned cGMP facility in Mequon, WI built for testing, ✓ Manufacturing Quality & Scale constrained industry-wide. quality assurance,
Slide 20: Valor Molecular Instruction
INTRODUCING Valor Molecular Instruction The Valor platform decouples biological instruction from its delivery. The peptide provides the biological signal. Pulsed-magnetic nanoparticles provide the precision delivery. Together, they direct tissue response and support recovery. CATEGORY Molecular Inst
Slide 21: Molecular Instruction: A New Approach. A New Standard.
Molecular Instruction: A New Approach. A New Standard. BA MI COMPOUND EFFECT + = The expected result is accelerated tissue repair with pain Biomechanical Ecosystem Programmable Peptide mitigation. Activation Molecular Instruction Pain Mitigation Tissue Repair Regeneration IP Moat Direct modulation o
Slide 22: Valor by Vector
VALOR BY VECTOR Valor is the sports medicine division of Vector Science & Therapeutics Corp. (TSXV: PAIN), built to bring clinically sound transdermal peptide delivery to elite athletes and the sports medicine professionals who care for them. Dexter Fowler Gary Payton II Chief Athletic Officer, Valo
Slide 23: Delivering Peptides to Targeted Anatomy
PROJECT VALOR · PLATFORM THESIS Delivering Peptides to Targeted Anatomy PEPTIDES + TRANSDERMAL DELIVERY EE + MI PLATFORM THESIS Short chains of amino acids — the body's own signaling molecules. Smaller Platform Thesis than proteins, highly targeted in action. EE + MI: biomechanical ecosystem activat
Slide 24: Accelerating Healing and Repair.
Accelerating Healing and Repair. ENERGY TRANSDUCTION (EE) MOLECULAR INSTRUCTION (MI) Physical stimulus → better environment → adaptive cell response Peptide payload → receptor-ligand binding → exogenous cascade triggered PEMF — Wnt/β-catenin & A2A/A3 adenosine receptor upregulation; Not an environme
Slide 25: How We Win the Conversation
COMMERCIAL ARCHITECTURE · THE 5 LEVERS How We Win the Conversation Every other platform in this space optimizes the biological environment. Valor optimizes the environment (vasodilation, oxygenation, nutrient delivery) and instructs the repair with peptides. 1 Category Consolidation Place all EE pla
Slide 26: Two Lanes. One Convergence Point.
REGULATORY ARCHITECTURE · SEPARATION BY DESIGN Two Lanes. One Convergence Point. Device clearance on BA foundation. Peptides via physician prescription. Combination product review avoided by design. Lane 1 — Device · 510(k) Clearance Lane 2 — Peptides · Physician Prescription EE Foundation Claim Onl
Slide 27: The Three-Layer Moat
COMPETITIVE MOAT · VERTICALLY INTEGRATED The Three-Layer Moat No standalone BA player can replicate without years of infrastructure investment. MI FORMULATION FOUNDATION CGMP BACKBONE PRESCRIBER DISTRIBUTION LyoGenesis Plus Verlytix Direct to Prescriber Lyophilization bridges biological potency and
Slide 28: The Four-Target Causal Cascade
PROJECT VALOR · THERAPEUTIC FOCUS The Four-Target Causal Cascade Target BA Ceiling MI Advantage Inflammation — Gatekeeper Modulate cytokine expression; reduce inhibitory signals Direct instruction: halt IL-1β, IL-6, TNF-α; upregulate IL-10 Reduce inflammatory tone that sustains pain; improve Direct
Slide 29: VectorMist atomization catheter platform
VectorMist is the atomization catheter platform that delivers site-directed pain mitigation therapeutics across the surgical field, extending pain control beyond the operating room (48–72 hours). The clinical priority is to reduce reliance on rescue opiate use in the postoperative phase.
Slide 30: Systemic Delivery Is Failing Patients
THE PROBLEM Systemic Delivery Is Failing Patients 107,000+ 65+ 50% Drug Overdose Deaths Annually (U.S.) Average Age with 5+ Chronic Conditions Of Seniors Take 5+ Medications Daily Opioid prescriptions for pain management Degenerative disease treated with more pills Polypharmacy creates cascading dru
Slide 31: Laparoscopic Atomization. Mitigating Systemic Burden.
VECTORMIST · COMMERCIAL LAUNCH Q4 2026 Laparoscopic Atomization. Mitigating Systemic Burden. 1 2 3 4 Catheter-based system inserted into Atomizes surgeon-defined LASSO Mist delivers homogeneous coverage of Faster recovery, same-day discharge, laparoscopic port Protocol drug combination the peritonea
Slide 32: LASSO Protocol
LASSO Protocol Establishing the Clinical Standard for Opioid-Sparing Laparoscopic Surgery. The multimodal, non-systemic approach is designed to support measurable improvements aligned with facility efficiency goals and the surgical community's growing emphasis on reducing opioid dependence. L Laparo
Slide 33: Market Penetration & Growth
VECTORMIST · REVENUE PROJECTION Market Penetration & Growth $325M 41% 4.8M 2032 Revenue Projection CAGR, 2028–2032 Annual U.S. laparoscopic procedures Fiscal Year Market Penetration Units Captured Facilities FY 2027 0.26% 12,480 units 78 facilities FY 2028 0.55% 28,000 units 175 facilities FY 2029 0
Slide 34: Precision Targeting. Four Key Channels.
GO-TO-MARKET · CHANNEL STRATEGY Precision Targeting. Four Key Channels. CLINICAL CHAMPIONS PROTOCOL VALIDATORS PERIOPERATIVE INTEGRATORS INSTITUTIONAL GATEKEEPERS High-Volume Laparoscopic Surgical Society KOLs Anesthesiology Partners ASC Medical Directors Surgeons 20+ laparoscopic cases per month. S
Slide 35: Platform to Portfolio
ty VECTOR Platform to Portfolio
Slide 36: VectorMist + Valor: 2027–2032
REVENUE PROJECTIONS · TOTAL PORTFOLIO VectorMist + Valor: 2027–2032 $774M $325M $449M 2031 2032 Combined Portfolio Revenue VectorMist 2032 Projection Project Valor 2032 Projection Valor Surpasses VectorMist VectorMist + Project Valor 41% CAGR 2028–2032 4,800 prescribers, Q4 2032 Recurring patch reve
Slide 37: Protected Position. Partner Ecosystem.
INTELLECTUAL PROPERTY · STRATEGIC PARTNERSHIPS Protected Position. Partner Ecosystem. PATENT & TRADEMARK PORTFOLIO STRATEGIC PARTNERSHIPS 15 7 LyoGenesis Plus: cGMP Lyophilization Partner Pharmaceutical-grade lyophilization and manufacturing partner for LASSO Protocol drug combinations. Co-founder B
Slide 38: Meet the Team
LEADERSHIP Meet the Team Science · Engineering · Clinical · Regulatory · Commercial · Financial Tommy Thompson Bill Jackson Barry Hix Tom Bachinski Chairman Co-Founder & CEO Co-Founder & CCO Co-Founder & CTO ▸ 45th Governor of Wisconsin ▸ Deep experience leading ▸ 25+ years at Merck, HealthSouth, ▸
Slide 39: Leadership Team
LEADERSHIP TEAM Dr. W. Bradley Worthington Tabitha Hendren Co-Founder & Chief Medical Officer Director, Engineering & Design ▸ Triple board-certified in anesthesiology, critical care medicine, and pain medicine ▸ University of Michigan-trained biomedical engineer (undergrad and masters) ▸ Designed a
Slide 40: Key Investment Risks
RISK FACTORS · SUMMARY Key Investment Risks ! Early-Stage Company Risk ! Regulatory Risk Vector has a limited operating history, no products approved for commercial FDA 510(k) clearance is not guaranteed. Delays, additional data requirements, sale, and no product revenues to date. Investors should e
Slide 41: Capitalization Table
SINCE TSXV LISTING · Q2 2026 Capitalization Table 153,490,560 90,095,950 243,586,510 Vested-In-The-Money Options & Basic Shares Outstanding Fully Diluted Shares Outstanding Warrants* Note: Approximately 137 mln shares and 80 mln wts are controlled by friends, family and insiders. Management and insi
Slide 42: Bringing the Science of Precision to Therapeutics
Bringing the Science of Precision to Therapeutics The Vector Science & Therapeutics Team info@vectorscience.co · vectorscience.co · Mequon, Wisconsin · TSXV: PAIN Confidential — For Accredited Investors Only
Vector Science & Therapeutics — Investor Presentation (July 2026) on 6ix